Tag: mRNA

The definitive agreements for equity investment of EUR 15 million in Ethris GmbH will fast-track Cipla’s participation in the mRNA space

Click to Read: BioVoice eMagazine December 2022 Issue 3 Volume 3 The Cover Story in the current edition focuses on India's strong biotech R&D segment...

A research team led by Sandeep M Eswarappa, Associate Professor, Department of Biochemistry, Indian Institute of Science, Bengaluru, has identified that mature human RBCs can also make their proteins

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

In 2021, leading mRNA vaccines, Comirnaty and Spikevax, generated combined sales of more than $54 billion globally and are expected to generate similar or greater sales in 2022

First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older

Subject to the regulatory approval, Moderna is ready to ship bivalent booster mRNA-1273.222 in September

To be sold under the brand name GEMCOVAC™-19, the two dose vaccine will be available for adults above 18 years of age and administered intramuscularly at 28 days apart

The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere

Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle